title: The role of targeted therapy in ovarian cancer.
abstract: Ovarian cancer is the second most common gynaecological malignancy and the leading cause of death from gynaecological cancer. Although in some cases treatment is initially effective, there is a considerable risk of disease recurrence and resistance to therapy. Therapies targeting molecular alterations in tumours offer the promise of significantly improved treatment. So far, the most promising targeted agents are angiogenesis inhibitors and PARP inhibitors. Here, we review the various targeted therapeutic approaches under clinical investigation in phase I and II trials of ovarian cancer and the challenges facing their future success in the clinic.
authors.affiliation: The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom.
authors.forename: Susana
authors.initials: S
authors.lastname: Banerjee
authors.forename: Stan
authors.initials: S
authors.lastname: Kaye
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D002277:Carcinoma / Q000098:blood supply / Q000628:therapy*; D017321:Clinical Trials, Phase I as Topic / Q000379:methods; D017322:Clinical Trials, Phase II as Topic / Q000379:methods; D005260:Female; D006801:Humans; D008954:Models, Biological; D058990:Molecular Targeted Therapy / Q000379:methods* / Q000706:statistics & numerical data; D010051:Ovarian Neoplasms / Q000098:blood supply / Q000628:therapy*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D000970:Antineoplastic Agents; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A